Kiora Pharmaceuticals (KPRX)
(Real Time Quote from BATS)
$3.38 USD
-0.28 (-7.65%)
Updated Sep 16, 2024 01:54 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Kiora Pharmaceuticals, Inc. [KPRX]
Reports for Purchase
Showing records 1 - 18 ( 18 total )
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reverse Stock Split Effected; Reiterate Buy; Adjusting PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Partnership in Retinal Diseases Inked; Reiterate Buy; Adjusting PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
KIO-301 Improves Vision in Blind Patients with RP; Reiterate Buy; Raising PT to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
U.S. and European Patents for KIO-100 Family Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q23 Results; Pipeline Shift; Reiterate Buy; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q23 Financial Results Reported; Reiterate Buy; Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
First Patient Enrolled With Ocular Presentation of Autoimmune Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
2022 Financial Results Reported; Reiterate Buy; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2 Trial in Ocular Presentation of Autoimmune Diseases to Begin Enrollment in 1H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2 PCED Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q22 Financial Results Reported; Reiterate Buy; Instituting $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q22 Financial Results Reported; Reiterate Buy; Adjusting PT to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
2021 Financial Results Reported; Reiterate Buy; Lowering PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Kiora Pharmaceuticals, Inc.
Industry: Medical - Drugs
Kiora Reports 3Q21 Results; Reiterate Buy; Instituting $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
|